<DOC>
	<DOC>NCT02343172</DOC>
	<brief_summary>To determine the MTD/RP2D of the HDM201 and LEE011 combination and evaluate whether the combination is safe and has beneficial effects in patients with liposarcoma.</brief_summary>
	<brief_title>Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma</brief_title>
	<detailed_description />
	<mesh_term>Liposarcoma</mesh_term>
	<criteria>Patients with histologically documented, locally advanced or metastatic WD/DD liposarcoma who have received at least one prior systemic therapy Patients with radiologic progression, defined by RECIST v.1.1, occurring while on/or within 6 months after last systemic treatment, prior to enrollment ECOG performance status of 01 Prior treatment with compounds with the same mode of action Patients with TP53 mutated tumors, if the molecular status is known Symptomatic central nervous system metastases Inadequate organ function Previous and concomitant therapy that precludes enrollment, as defined by protocol Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Liposarcoma,</keyword>
	<keyword>MDM2 inhibition,</keyword>
	<keyword>cdk4 inhibition,</keyword>
	<keyword>HDM201,</keyword>
	<keyword>LEE011</keyword>
</DOC>